{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:20:32Z","timestamp":1792106432118,"version":"4.4.0"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:00:00Z","timestamp":1713484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disorder. Dementia severity was assessed mainly through cognitive function, psychobehavioral symptoms, and daily living ability. Currently, there are not many drugs that can be selected to treat mild to moderate AD, and the value of drugs remains controversial.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>The aim of this study is to quantitatively evaluate the efficacy and safety of cholinesterase inhibitors (ChEIs), memantine, and sodium oligomannate (GV-971) in the treatment of patients with AD. Additionally, molecular docking analysis will be used to investigate the binding affinities of donepezil, galantamine, rivastigmine, and memantine with key receptor proteins associated with AD, including beta-amyloid (Abeta), microtubule-associated protein (MAP), apolipoprotein E4 (APOE4), and Mitofusin-2 (MFN2), to further validate the results of the meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We obtained clinical trials characterized by randomization, placebo control, and double\u2013blinded methodologies concerning ChEIs, memantine, and GV-971. Statistical analysis was performed using Review Manager Version 5.4 software. Molecular docking was also conducted to evaluate the results.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>All drugs improved the cognitive function, with the effect value ranging from \u22121.23 (95% CI \u22122.17 to \u22120.30) for 20\u2009mg memantine to \u22123.29 (95% CI \u22124.14 to \u22122.45) for 32\u2009mg galantamine. Although 32\u2009mg galanthamine and GV-971 did not improve the clinicians\u2019 Global Impression of Change scale, other drugs showed significant results compared with placebo. On NPI, only 10\u2009mg of donepezil and 24\u2009mg of galantamine had improvement effects. On ADCS\/ADL, only 20\u2009mg memantine and 900\u2009mg GV-971 had no significant difference from the placebo. Donepezil 5\u2009mg and GV-971 900\u2009mg did not increase the drug withdrawal rates due to various reasons or adverse reactions when compared to the placebo. Donepezil demonstrated superior binding to the protein and exhibited greater efficacy compared to other drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>ChEIs, memantine, and GV-971 all can slow the progression of AD but have different effects on respective assessments. Donepezil and GV-971 were relatively well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000037799","type":"journal-article","created":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T18:06:19Z","timestamp":1713549979000},"page":"e37799","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Evaluating the efficacy and safety of Alzheimer\u2019s disease drugs: A meta-analysis and systematic review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5849-3990","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"first","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lai","sequence":"additional","affiliation":[{"name":"The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-4390","authenticated-orcid":false,"given":"Ming","family":"Tao","sequence":"additional","affiliation":[{"name":"The Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ebiom.2016.03.035","article-title":"The Role of Amyloid-\u03b2 oligomers in toxicity, propagation, and immunotherapy.","volume":"6","author":"Sengupta","year":"2016","journal-title":"EBioMedicine"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s Disease: causes and treatment.","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2174\/1567205015666180119092427","article-title":"Estimating Alzheimer\u2019s Disease progression rates from normal cognition through mild cognitive impairment and stages of Dementia.","volume":"15","author":"Davis","year":"2018","journal-title":"Curr Alzheimer Res"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease.","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"120861","DOI":"10.1016\/j.lfs.2022.120861","article-title":"Alzheimer\u2019s disease failed clinical trials.","volume":"306","author":"Asher","year":"2022","journal-title":"Life Sci"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"e30858","DOI":"10.1097\/MD.0000000000030858","article-title":"Research status, hotspots and trends of acupuncture and moxibustion in the treatment of Alzheimer\u2019s disease: a bibliometric analysis.","volume":"101","author":"Yue","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000316119","article-title":"Nonpharmacological therapies in Alzheimer\u2019s disease: a systematic review of efficacy.","volume":"30","author":"Olazar\u00e1n","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neurobiolaging.2023.04.005","article-title":"Gamma neuromodulation improves episodic memory and its associated network in amnestic mild cognitive impairment: a pilot study.","volume":"129","author":"Jones","year":"2023","journal-title":"Neurobiol Aging"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1089300","DOI":"10.3389\/fnins.2023.1089300","article-title":"Altered glutamate-glutamine and amide proton transfer-weighted values in the hippocampus of patients with amnestic mild cognitive impairment: a novel combined imaging diagnostic marker.","volume":"17","author":"Chen","year":"2023","journal-title":"Front Neurosci"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"1163809","DOI":"10.3389\/fnins.2023.1163809","article-title":"Magnetic resonance imaging of white matter in Alzheimer\u2019s disease: a global bibliometric analysis from 1990 to 2022.","volume":"17","author":"Yue","year":"2023","journal-title":"Front Neurosci"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"1244696","DOI":"10.3389\/fneur.2023.1244696","article-title":"Functional brain activity in patients with amnestic mild cognitive impairment: an rs-fMRI study.","volume":"14","author":"Yue","year":"2023","journal-title":"Front Neurol"},{"issue":"12 Suppl","key":"R12-20250503","first-page":"5","article-title":"American Psychiatric Association practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias. Second edition.","volume":"164","author":"Rabins","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease.","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease.","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"issue":"Suppl 2","key":"R17-20250503","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1212\/WNL.44.12.2315","article-title":"The Clinician Interview-Based Impression (CIBI): a clinician\u2019s global change rating scale in Alzheimer\u2019s disease.","volume":"44","author":"Knopman","year":"1994","journal-title":"Neurology"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer\u2019s disease - results from a multinational trial.","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group.","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000017259","article-title":"Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer\u2019s disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.","volume":"11","author":"Homma","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1185\/030079902125001029","article-title":"Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer\u2019s disease.","volume":"18","author":"Gauthier","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","article-title":"Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.","volume":"61","author":"Seltzer","year":"2004","journal-title":"Arch Neurol"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study.","volume":"26","author":"Maher-Edwards","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13195-016-0210-1","article-title":"ABT-126 monotherapy in mild-to-moderate Alzheimer\u2019s dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.","volume":"8","author":"Gault","year":"2016","journal-title":"Alzheimers Res Ther"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer\u2019s disease: multicentre randomised controlled trial. Galantamine International-1 Study Group.","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer\u2019s disease.","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer\u2019s disease: international randomised controlled trial.","volume":"318","author":"R\u00f6sler","year":"1999","journal-title":"BMJ"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/jnnp.2006.099424","article-title":"Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer\u2019s disease.","volume":"78","author":"Feldman","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/gps.1788","article-title":"A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer\u2019s disease--rivastigmine patch versus capsule.","volume":"22","author":"Winblad","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"key":"R34-20250503","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","article-title":"Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.","volume":"14","author":"Peskind","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3233\/JAD-2008-13110","article-title":"Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease: results of a randomised, double-blind, placebo-controlled 6-month study.","volume":"13","author":"Bakchine","year":"2008","journal-title":"J Alzheimers Dis"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13195-020-00678-3","article-title":"A phase II randomized trial of sodium oligomannate in Alzheimer\u2019s dementia.","volume":"12","author":"Wang","year":"2020","journal-title":"Alzheimers Res Ther"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13195-021-00795-7","article-title":"A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer\u2019s dementia.","volume":"13","author":"Xiao","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/CIA.S129145","article-title":"Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson\u2019s disease dementia.","volume":"12","author":"Kandiah","year":"2017","journal-title":"Clin Interv Aging"},{"key":"R39-20250503","first-page":"1479","article-title":"Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (Review).","volume":"20","author":"Sharma","year":"2019","journal-title":"Mol Med Rep"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","article-title":"Alzheimer\u2019s disease.","volume":"388","author":"Scheltens","year":"2016","journal-title":"Lancet"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression.","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res"},{"issue":"Pt 11","key":"R43-20250503","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/brain\/awl251","article-title":"Alzheimer\u2019s centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway.","volume":"129","author":"Masters","year":"2006","journal-title":"Brain"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","article-title":"ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies.","volume":"17","author":"Raulin","year":"2022","journal-title":"Mol Neurodegener"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3390\/jcm9010126","article-title":"Back to the fusion: Mitofusin-2 in Alzheimer\u2019s Disease.","volume":"9","author":"Sita","year":"2020","journal-title":"J Clin Med"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ije\/21.5.837","article-title":"Intention-to-treat analysis: implications for quantitative and qualitative research.","volume":"21","author":"Newell","year":"1992","journal-title":"Int J Epidemiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:09:10Z","timestamp":1746317350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,19]]},"references-count":43,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037799","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,19]]}}}